跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
在 國立陽明交通大學研發優勢分析平台 搜尋內容
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
查看斯高帕斯 (Scopus) 概要
林 志慶
教授
醫學系內科學科
電子郵件
lincc2
vghtpe.gov
tw
h-index
h10-index
h5-index
2807
引文
30
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1099
引文
17
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
532
引文
11
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1998 …
2026
每年研究成果
概覽
指紋
網路
研究成果
(184)
類似的個人檔案
(6)
指紋
查看啟用 Chih-Ching Lin 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Hemodialysis Patients
78%
Hemodialysis
46%
Peritoneal Dialysis
41%
Far-infrared Therapy
35%
Chronic Kidney Disease
31%
Peritoneal Dialysis Patients
28%
Arteriovenous Fistula
28%
Vascular Access
27%
Taiwan
25%
Maintenance Hemodialysis Patients
22%
Patency
20%
Dialysis
15%
Hazard Ratio
15%
Uremic Patients
14%
Heme oxygenase-1 (HO-1)
13%
Arteriovenous Graft
13%
Risk Factors
13%
Acrolein
12%
National Cohort Study
12%
Randomized Controlled Trial
12%
Diabetic Kidney Disease
12%
Asymmetric Dimethylarginine
12%
Hemodialysis Vascular Access
12%
Continuous Erythropoietin Receptor Activator
11%
End-stage Renal Disease
11%
Clinical Outcomes
10%
Erythropoiesis-stimulating Agents
10%
Kidney Fibrosis
10%
Arteriovenous Fistula Patency
10%
Proteinuria
10%
Peritoneal Dialysis Catheter Insertion
10%
Dialysis Membrane
10%
95% Confidence Interval
9%
Hematocrit
9%
Kidney Disease
9%
Kidney Function
9%
Aldehyde Dehydrogenase 2 (ALDH2)
9%
Retrospective Cohort Study
9%
Dialysis Patients
8%
Yoga
8%
COVID-19
7%
High Risk
7%
Perfluorohexane Sulfonate (PFHxS)
7%
Atrial Fibrillation
7%
Far-infrared
7%
Genotype
7%
Hypoglycemia
7%
Mitochondrial Dysfunction
7%
Vascular Thrombosis
7%
Hypertension
7%
Medicine and Dentistry
Hemodialysis
100%
Peritoneal Dialysis
57%
Vascular Access
40%
Arteriovenous Fistula
32%
Heat Therapy
31%
Chronic Kidney Disease
29%
End Stage Renal Disease
22%
Prevalence
12%
Diabetes Mellitus
10%
Dialysis Catheter
10%
Hazard Ratio
10%
Proteinuria
9%
Randomized Controlled Trial
9%
Yoga
9%
Thrombosis
9%
N(g),n(g) Dimethylarginine
9%
Nephrology
9%
Blood Pressure
8%
Creatinine
8%
Cardiovascular System
8%
Nephropathy
7%
Cohort Analysis
7%
Glomerulonephritis
7%
Cohort Effect
7%
Prognostic Factor
7%
Kidney Function
7%
ACE Inhibitor
7%
Apoplexy
7%
Urinary System
7%
Cardiovascular Disease
6%
Immunosuppressant
6%
Ankle Brachial Index
6%
Hypoglycemia
6%
Pneumocystis Pneumonia
6%
Polycystic Kidney Disease
6%
Nodular Goiter
6%
Thyroid Disease
6%
Angiotensin Receptor Antagonist
6%
Heme Oxygenase 1
5%
Infection
5%
Renin Angiotensin Aldosterone System
5%
Therapeutic Modality
5%
Quality of Life
5%
Health Care Cost
5%
Pharmacology, Toxicology and Pharmaceutical Science
Hemodialysis
80%
Arteriovenous Fistula
22%
Inflammation
16%
Acrolein
15%
Cohort Study
15%
End Stage Renal Disease
13%
Chronic Kidney Failure
13%
Coronavirinae
12%
Congestive Heart Failure
12%
Continuous Erythropoiesis Receptor Activator
11%
Diabetic Nephropathy
11%
Diseases
10%
Aldehyde Dehydrogenase Isoenzyme 2
9%
Diabetes Mellitus
8%
Coronary Artery Disease
8%
Atrial Fibrillation
8%
Creatinine
8%
Perfluorooctanesulfonic Acid
8%
C Reactive Protein
8%
Hypertension
8%
Cardiovascular Disease
7%
Infection
7%
Acute Kidney Failure
7%
Dipeptidyl Carboxypeptidase Inhibitor
7%
Cerebrovascular Accident
7%
Angiotensin Receptor Antagonist
6%
Pathophysiology
6%
Lipid
6%
Randomized Controlled Trial
6%
6 N,n' Dimethylarginine
6%
N(g),n(g) Dimethylarginine
6%
Dipeptidyl Peptidase IV Inhibitor
6%
Valsartan/Sacubitril
6%
Heme Oxygenase 1
6%
Glucose
5%
Kidney Disease
5%
Angiotensin
5%
Renin
5%
Heart Failure with Reduced Ejection Fraction
5%
